Categories Cannabis, Earnings

GW Pharmaceuticals stock jumps 20% on Epidiolex strength

GW Pharmaceuticals (NASDAQ: GWPH) reported third-quarter 2020 financial results before the regular trading hours on Tuesday. The company, which specializes in cannabinoid prescription medicines, reported a 51% spike in Q3 revenue to $137.1 million, surpassing the Wall Street consensus. Net earnings narrowed to 0.03 per share, stronger than the target that analysts had projected.

GWPH shares gained 19% during market hours. The stock has increased 4% since the beginning of this year.

GW Pharmacueticals Q3 2020.

Looking forward to listening to management/ analyst comments on Q3 results? Stay tuned here for GW Pharmaceuticals Q3 2020 earnings call transcript

Epidiolex accounted for a lion’s share of the total revenues, contributing $132.6 million in Q3.

CEO Justin Gover said, “We have also now commenced the pivotal Phase 3 program for nabiximols in the treatment of multiple sclerosis spasticity, which provides multiple opportunities for an NDA submission, including as early as next year. Beyond nabiximols, we are advancing several clinical-stage pipeline candidates, including the recent start of a Phase 2 trial in schizophrenia.”

____

Most Popular

UAL Earnings: United Airlines Q4 revenue Jumps; net loss narrows

Aviation giant United Airlines Holdings, Inc. (NYSE: UAL) reported a narrower net loss for the fourth quarter of 2021 as the company's revenues more than doubled during the period. The

Microsoft (MSFT), Activision (ATVI), Take-Two (TTWO), Zynga (ZNGA): Get ready for a new era in gaming

Over the past two weeks, the gaming industry has witnessed some key developments, namely the Microsoft-Activision and Take-Two Interactive-Zynga deals. These are major transactions that could herald a new era

Bank of America reports mixed Q4 results

Bank of America (NYSE: BAC) reported fourth-quarter 2021 financial results before the regular market hours on Wednesday. The banking giant reported Q4 revenue of $22.17 million, up 10% year-over-year, but

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top